This resulted in the discovery of GDC-0941(compound 13, PI3Kα/β/δ/γ IC50 = 3/3.3/3/7.5 nM, mTOR IC50 = 0.58μM), a potent, selective, orally bioavailable inhibitor of Class I PI3K including the p110α mutant enzymes, and is currently being evaluated in human clinical trials for cancer treatment. The gene discussed is MTOR; the disease is cancer.